Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our country websites.
-
Roivant subsidiary Dermavant Sciences signs agreement with GSK to purchase rights to tapinarof
GSK today announced that Dermavant Sciences, a subsidiary of Roivant Sciences, has agreed to purc...
Read more -
Infants may now be protected against Meningitis B with fewer doses, adding flexibility to vaccination schedules
Healthcare professionals now have more options to help protect infants from invasive meningococca...
Read more -
ViiV Healthcare reports landmark phase III studies for dolutegravir and lamivudine, demonstrating the ability to control HIV with a two-drug regimen in treatment naïve patients
GEMINI 1&2 studies meet primary endpoint, demonstrating similar efficacy of two-drug regimen comp...
Read more -
GSK presents new results showing low rates of organ damage with long term use of Benlysta
GSK today announced results from two new analyses showing low rates of organ damage progression i...
Read more -
GSK announces changes to Vaccines and Global Manufacturing & Supply leadership
Luc Debruyne, President, Vaccines, is to leave GSK at the end of the year.
Read more -
GSK completes Consumer Healthcare buyout
GSK has completed the buyout of Novartis’ 36.5% stake in its Consumer Healthcare Joint Venture fo...
Read more -
GSK submits regulatory application in Japan for once-daily single inhaler triple therapy FF/UMEC/VI for patients with COPD
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the submiss...
Read more -
ViiV Healthcare receives EU marketing authorisation for Juluca (dolutegravir/rilpivirine), the first 2-drug regimen, once-daily, single-pill for the treatment of HIV
Juluca maintains viral suppression with two drugs in the smallest single pill regimen
Read more -
GSK receives US approval of Arnuity Ellipta for use in children from 5 years old who suffer from asthma
GSK today announced it has received approval from the US Food and Drug Administration (FDA) for t...
Read more -
Nucala (mepolizumab) study reports long-term safety data, consistent exacerbation reduction and improved asthma control
New study showed one third of patients had no exacerbations on long-term treatment with Nucala.
Read more -
GSK’s industry-leading respiratory research and scientific innovation showcased at ATS conference
GlaxoSmithKline plc (GSK) will present extensive data from across its respiratory portfolio, pipe...
Read more -
Simon Dingemans, Chief Financial Officer, to retire from GSK
Simon Dingemans, Chief Financial Officer (CFO), GSK, has informed the Board of his intention to r...
Read more -
GSK delivers Q1 sales of £7.2 billion, -2% AER, +4% CER
Total EPS 11.2p, -48% AER, -33% CER; Adjusted EPS 24.6p, -2% AER, +11% CER
Read more -
Once-daily Trelegy Ellipta gains expanded indication in the US for the treatment of patients with COPD
Expanded indication approved for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF...
Read more -
Landmark IMPACT study published in NEJM shows significant benefits of Trelegy Ellipta for patients with COPD
Once-daily single inhaler triple therapy superior to Relvar/Breo Ellipta and Anoro Ellipta across...
Read more -
GSK appoints Kevin Sin as new SVP and Head of Worldwide Business Development for R&D
Kevin Sin appointed as Senior Vice President and Head of Worldwide Business Development for Pharm...
Read more -
GSK signs strategic agreement to transfer rare disease gene therapy portfolio to Orchard Therapeutics
Agreement strengthens Orchard’s position as a global leader in gene therapy for rare diseases. GS...
Read more -
GSK reaches agreement with Novartis to acquire full ownership of Consumer Healthcare Business
GSK reaches agreement with Novartis to acquire full ownership of Consumer Healthcare Business
Read more -
ViiV Healthcare gains CHMP positive opinion for Juluca (dolutegravir/rilpivirine) in Europe
ViiV Healthcare today announced that the European Committee for Medicinal Products for Human Use ...
Read more -
Shingrix approved in Europe and Japan for the prevention of shingles in adults aged 50 and over
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the European Commission has approved Shi...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines
-
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
